RT Journal Article
SR Electronic
T1 Sequential mosaic variants in <em>KRAS</em> and <em>STAT5B</em> associated with a mixed phenotype of two acquired errors of immunity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.07.24311150
DO 10.1101/2024.08.07.24311150
A1 Forkgen, Julia
A1 Masle-Farquhar, Etienne
A1 Fontaine, Yves
A1 Russell, Amanda
A1 Ji, Shannon
A1 Peters, Timothy J
A1 Qiao, Zhen
A1 Geaghan, Michael
A1 Jackson, Katherine JL
A1 Hammond, Jillian M
A1 Deveson, Ira W
A1 David, Clementine
A1 Lemberg, Daniel A
A1 Gupta, Nitin
A1 Fuentes-Bolanos, Noemi
A1 Mustjoki, Satu
A1 Hwa, Vivian
A1 Tangye, Stuart G
A1 Gray, Paul E
A1 Siggs, Owen M
YR 2024
UL http://medrxiv.org/content/early/2024/08/08/2024.08.07.24311150.abstract
AB Mosaic genetic variation has been implicated in the pathogenesis of both malignant and non-malignant immunological disease. Here, we report a unique case of postnatal acquisition of a gain-of-function (GoF) KRAS variant, with an additional GoF STAT5B variant, in a woman with inflammatory bowel disease, splenomegaly, thrombocytopenia, bronchiectasis, monocytosis, and eosinophilia. Targeted amplicon sequencing revealed widespread distribution of both variants in key immune cell populations, and in historical blood and tissue samples, with the emergence of both variants coinciding with the time of clinical presentation. Short- and long-read single cell RNA sequencing of patient cells highlighted a unique population of monocytes, with a broad distribution of both variants, and dysregulated cytokine signaling pathways. Flow cytometry revealed dysregulated STAT signaling, and the presence of a distinct population of highly granular CD24+ cells. Taken together with the clinical presentation, these findings led to a diagnosis of combined RAS-associated autoimmune leukoproliferative disorder (RALD) and non-clonal STAT5B GoF disease. To our knowledge, this is the first reported combination of two distinct acquired errors of immunity causing a mixed clinical phenotype, and highlights the importance of considering acquired monogenic diseases within a broader genomic context.Competing Interest StatementO.M.S. holds equity in Seonix Pty Ltd.. I.W.D. has a paid consultant role with Sequin Pty Ltd, and has previously received travel and accommodation expenses from ONT to speak at conferences. The authors declare no other competing interests.Funding StatementThis study was supported by a Snow Medical Fellowship (to OMS). SGT is supported by an Investigator Grant awarded by the National Health and Medical Research Council (NHMRC) of Australia (Level 3; 1176665).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics review committee of Sydney Local Health District gave ethical approval for this work. Human research ethics committee of Western Sydney Local Health District gave ethical approval for this work. Ethics committee of Cincinnati Children's Hospital Medical Center gave ethical approval for this work. Ethics committee of Helsinki University Central Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors